product name Dexlansoprazole
Description: Dexlansoprazole (also known as Dexilant and TAK-390MR), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties by employing a novel release formulation that prolongs its absorption. Dexlansoprazole is used to treat non-erosive gastroesophageal reflux disease.
References: Aliment Pharmacol Ther. 2009 May 1;29(9):928-37; Clin Ther. 2010 Aug;32(9):1578-96.
369.36
Formula
C16H14F3N3O2S
CAS No.
138530-94-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 74 mg/mL (200.3 mM)
Water: <1 mg/mL
Ethanol: 74 mg/mL (200.3 mM)
Solubility (In vivo)
Synonyms
T 168390，TAK 390
other peoduct :
| In Vitro |
In vitro activity: Dexlansoprazole, constitutes >80% of circulating drug after oral administration of lansoprazole, provides lower clearance and 5-fold greater systemic exposure than the S-enantiomer following oral administration of lansoprazole. Dexlansoprazole MR is a modified release formulation of dexlansoprazole, which employs a novel Dual Delayed Release (DDR) technology that delivers the drug in two discrete phases of release, thereby inhibiting newly activated proton pumps that turn over following initial PPI inactivation of H+,K+-ATPase. Dexlansoprazole MR maintains plasma drug concentrations above the threshold level longer than lansoprazole at all doses, resulting in an optimized drug exposure-intragastric pH relationship. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H+K+-ATPase proton pump in the gastric parietal cell, inhibition of this cell membrane enzyme ultimately blocks the final step in acid production. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Aliment Pharmacol Ther. 2009 May 1;29(9):928-37; Clin Ther. 2010 Aug;32(9):1578-96. |
